Introduction
The prevalence of diabetes has increased dramatically over the last half century, despite public health efforts to restrain it. 1, 2 Diabetes is an important risk factor for cardiovascular disease, and the health costs associated with treating the disease and its sequelae are considerable. Surveillance of diabetes prevalence is important to assist resource allocation decisions, assess the efficacy of nutrition regulation and health promotion programmes intended to reduce the incidence of this disorder, monitor services, and inform quality-ofcare programmes for diabetes.
Regular large community surveys would be the ideal way to assess trends in diabetes prevalence, but two major problems beset this approach: non-response bias and expense. Non-response bias limits the generalisability of results and may bias estimates. Further, response rates to community surveys have been falling over the past 25 years.
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What we already know: Extensively linked health data may indicate whether individuals in the new Zealand population have diabetes. This information may be aggregated to derive population estimates of diabetes prevalence; however, the accuracy of this method is unknown.
What this study adds:
Combined diabetes drug use, laboratory test, hospital diagnosis, and outpatient clinic data show high-level agreement with an independently derived primary care diagnosis of diabetes. such methods can yield an accurate estimate of prevalence of diagnosed diabetes in new Zealand.
For example, the 2006 New Zealand Health Survey had a non-response rate of 30%. 3 An alternative to surveys is the use of health-related administrative datasets. In New Zealand the National Health Index (NHI) number is a unique identifier that is assigned to almost all New Zealand residents (98% in 2008). This allows the merging of different records to develop a picture of an individual's health and treatment received. Use of some drugs is largely limited to the treatment of single diseases; thus oral hypoglycaemic agents and insulin are almost exclusively restricted to the treatment of diabetes. From this assumption, dispensing lists may be combined with recorded hospital discharge diagnoses of diabetes to infer that an individual has diabetes.
We have been investigating the use of linked national health datasets for several years to assess diabetes prevalence and these are currently used to plan health services. The accuracy of diabetes risk assessed using PREDICT™, which is a webbased clinical decision support system, to generate a Framingham-based cardiovascular risk assessment and provide patient-specific management advice. PREDICT™ automatically writes the risk profile to the patient's electronic health record and also anonymously stores a copy on a secure Surveillance of diabetes prevalence is important to assist resource allocation decisions, assess the efficacy of nutrition regulation and health promotion programmes… monitor services, and inform quality-of-care programmes for diabetes.
prevalence estimates derived from such combined datasets is uncertain. In the current study, we assessed their accuracy in a large primary carebased cohort which had its diabetes status formally documented while undergoing cardiovascular risk assessment. The level of under-count of diagnosed diabetes in the cohort was also estimated using capture-recapture methods.
Methods

Study population
We used diabetes diagnosis status in a cohort of 53 911 primary care patients who had completed a formal cardiovascular risk assessment as the comparator for assessing the validity of our derived diabetes prevalence estimate. The cohort had been server identified only by an encrypted NHI code. We used this latter database for our analyses.
The PREDICT TM cohort has been described elsewhere. 4 For these analyses, we used a subset of patients who had been risk assessed between 1 January 2007 and 15 December 2008 as part of routine primary care practice. This population consisted of 53 911 patients, mainly from the Auckland and Northland regions of New Zealand, who had attended primary care practices that use PREDICT™. They were expected to have a higher prevalence of diabetes than the general population because, at the time of these analyses, fewer than 20% of the eligible population had been assessed, and initial screening targeted higher-risk patients. Cohort participants who died during this period were excluded from the dataset. Therefore, all study participants were alive throughout the study period and had the same 'health exposure time' so that they could have been recorded in national datasets.
Documented primary care diagnosis of diabetes
As part of the risk assessment, general practitioners or practice nurses must assign a diabetes status to all patients on a template to either 'nodiabetes', 'type-1', 'type-2' or 'type-unknown'. A label of diabetes in the PREDICT TM cohort was assumed to be an accurate 'documented primary care diabetes diagnosis' because, when a patient was assigned a diagnosis of diabetes, a series of additional questions specifically relevant to this diagnosis automatically appeared on the template and had to be answered before the risk assessment could be completed and the data stored. This will be referred to as the 'Predict diabetes diagnosis' from here on.
Derived diagnosis of diabetes from national health data
A range of recorded health care activities from national, routinely collected health data was gathered on this Predict cohort, and combined to derive a diagnosis of diabetes to compare with the Predict diabetes diagnosis. Any appearance in one of the following four national lists was used as evidence of diabetes:
A hospital discharge diagnosis of diabetes 1.
anywhere among the coding (ICD 10: E10-E14, O24.0 to O24. In contrast to the Predict diabetes diagnosis, we refer to this indicator of diabetes as the 'derived diabetes diagnosis'. Five or more HbA1c test claims on the laboratory list in two years were used as the final criterion because preliminary investigation showed this cut-off resulted in the best agreement with the other three lists for patients diagnosed with diabetes.
Capture-recapture and statistical methods
To test whether the prevalence of diabetes diagnoses (from either method-Predict or derived) was complete, we estimated the overall prevalence of diagnosed diabetes in this cohort by using a statistical technique known as capturerecapture. Such a method links the three national lists most likely to accurately represent diabetes diagnoses (hospital discharge codes, hospital diabetes outpatient clinic visits, dispensing of diabetes drugs, and diabetes from Predict) to the counts found in intersecting combinations of these lists.
Each of these lists was considered a proxy for diagnosed diabetes, but none were expected to be complete; in contrast, capture-recapture methods estimate a 'virtual' complete total. Capture-recapture estimates of diabetes prevalence have been calculated in Italy 5 and the UK 6 using similar datasets to those available in New Zealand.
We used log-linear models to adjust for between-list dependence, using the Rcapture utility 7 of the R-project. 8 Numbers of people with diagnosed diabetes, in varying combinations of lists, were modelled as dependent variables; with independent variables comprising dummy indicators of the included lists. Interaction terms, which accounted for between-list dependence, were included in the models. The model with the least number of interaction terms that also demonstrated evidence of good model fit, was selected to estimate prevalence. Model fit was estimated by comparing Akaike's Information Criterion (AIC), chi-square statistics, and plots of Pearson residuals with predicted values, for competing models. All other calculations were carried out using the R-project (Epicalc 9 utility) or Microsoft Excel™. Scaled rectangle diagrams (similar to Venn diagrams) to display overlap in the datasets used for the combined list and capture-recapture methods were drawn using SPAN software. 10 qUAnTiTATiVE REsEARCH
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Results
The overall prevalence of a documented diagnosis of diabetes in the Predict cohort was 20.9% (11 266/53 911) ( Table 1 ). The Predict cohort also had higher proportions of males, Pacific and Maori ethnic groups and people of low socioeconomic status compared with proportions derived from census estimates (the final column in the Table 1 ). The highest prevalence of a documented diagnosis of diabetes was amongst South Asian people (38%; 873/2296), followed by Pacific peoples (35%; 3459/9910) and Maori (23%; 1988/8615). The remainder, who were mainly European, had a diagnosed diabetes prevalence of 15% (4946/33 090). People with diabetes were slightly older and a higher proportion were in low socioeconomic groups compared to those without such a diabetes diagnosis.
The agreement between groups with diabetesrelated activity identified from the four national datasets and those with a Predict diabetes diagnosis in the cohort was high, shown by the 
. Scaled rectangle diagram of agreement between combined list algorithm-based (CLE) label of diabetes and the primary care (PREDICT™) diagnosis of diabetes
scaled rectangle diagram (Figure 1 ). The outer rectangle represents the entire Predict cohort of 53 911 participants; the inner rectangles are the five overlapping groups with records of diabetesrelated activity in national datasets (elements of the derived diabetes diagnosis) or a Predict diabetes diagnosis. The rectangles are scaled according to size of the groups and the degree ORIGInAL sCIEnTIFIC PAPERs
Discussion
Our study showed high levels of agreement between a derived diabetes diagnosis, based on combining lists of national, routinely collected health data, and a diagnosis from a primary care database, in people undergoing CVD risk assessment. This suggests that the combined list method may be a useful surrogate for diagnosed diabetes to monitor trends in diabetes prevalence. Secondly, we showed that an electronic clinical decision support system used in routine primary care practice captures up to 90% of all diabetes diagnoses among patients to which it is applied.
The main strength of this study is that we had access to a large primary care cohort in which a documented diagnosis of diabetes is likely to be accurate. Further, the capture-recapture analyses indicated that use of the Predict system results in over 90% of all people with diabetes in the cohort being labelled appropriately.
Conversely, a limitation of the study was the nature of the sampling which led to entry into the Predict cohort. The Predict population had a higher proportion of people with diabetes (21%) compared to the general population, estimated at 4.3% (based on self-report from the last national health survey 3 ). This is likely to be due to many of the cohort participants being enrolled by their primary health care providers for a formal cardiovascular risk assessment, if they were believed to be at increased risk of developing CVD, by virtue of advanced age, or risk factors for the disease, or a combination of both.
The capture-recapture estimates of 'total' prevalence need to be interpreted with caution as they are limited by the assumptions that underlie their use. We used four lists, thought to be relatively specific for a diagnosis of diabetes; however, false positives may be present (e.g. metformin is sometimes used to treat polycystic ovarian syndrome) and may inflate prevalence estimates. Also, the number in intersecting lists is assumed to have a Poisson distribution (so that appearance on individual lists is independent of other subjects). Clustering of individuals on list counts by characteristics such as health service use, ethnic group, deprivation and age are likely to occur, and so the precision of the estimates may be overinflated. Another weakness is that patients who are treated with diet or lifestyle measures alone who have not been admitted or been to a diabetes clinic, would not be captured unless they had five or more HbA1c tests within two years-more than recommended by national guidelines. 11 The use of routinely collected national data has limitations. Because the datasets are not collected primarily for research purposes, significant heterogeneity in record collection in different administrative regions may occur. The completeness of linkage of health data by national health identifier has improved markedly over the last three to four years in New Zealand, but wider variability in the linkage of older health records used may affect the accuracy of the derived diagnosis method. These data quality issues should, however, improve further with time.
Internationally, authors have reported the use of derived diabetes prevalence from health records and capture-recapture estimates of diabetes prevalence, although not in the same study. The combined list estimate method has been used previously in Denmark 12 to describe time trends in diabetes prevalence between 1995 and 2006. The researchers used a similar technique to ours; however, five or more blood glucose measurements in a year, rather than aggregate numbers of HbA1c, was used as laboratory evidence of diabetes. A comparable study from Ontario used a rule that included a diagnosis in hospital discharge or outpatient records in the last two years as evidence that an individual has diabetes. 1 The sensitivity of the diabetes diagnosis associated with our derived diagnosis (89%) is similar to those quoted in Danish (85%) 12 and Canadian (86%) studies. 13 In contrast, a British study showed that the sensitivity of multiple record linkage, similar to the sources used in our study, was 91%, and more sensitive than general practice records.
14 Local attempts to define the prevalence of diabetes have included combining primary health care registers using diagnosis codes, diabetes medications, laboratory tests and screening programme registers. This method has shown high levels of concordance between the lists, similar to our results; however, the method is limited by qUAnTiTATiVE REsEARCH
ORIGInAL sCIEnTIFIC PAPERs organisational and geographic boundaries. 15 Our derived indicator of diabetes allows national prevalence of diabetes to be calculated.
Capture-recapture study examples include the Casale Monferrato study that monitored the prevalence of diabetes in this area of northwest Italy between 1988 and 2000. 5 Data from diabetes clinics, hospital discharge records, prescribing and sales of reagents and strips were combined to calculate population estimates. Comparing individual to capture-recapture methods, they found a diagnosis rate of about 80%, which is slightly lower than our estimate. In the United Kingdom similar capture-recapture studies of diabetes have been reported. 6, 16 We have previously carried out a more limited validation study of our derived diabetes prevalence method using a hospital-based diabetes register from a disease management programme as a gold standard. 17 We were aware that the register only included about half of the people with a diagnosis of diabetes in the population served by this hospital. Therefore, this earlier study was only able to assess the 'sensitivity' of the derived diagnosis. With these caveats, the proportion with a derived diagnosis, among those on the diabetes register (96%) from the earlier study, was higher than in the present analysis.
Conclusion
A derived indicator of diabetes diagnoses, based on linking routine national data, shows substantial agreement with a documented primary care diagnosis of diabetes. Routinely collected health data can provide a rapid and efficient way of monitoring the prevalence of diagnosed diabetes, and its change over time, with reasonable accuracy.
